Norges Bank Acquires New Position in Halozyme Therapeutics, Inc. $HALO

Norges Bank bought a new position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) during the 4th quarter, according to the company in its most recent filing with the SEC. The fund bought 1,904,922 shares of the biopharmaceutical company’s stock, valued at approximately $128,201,000.

Other large investors have also modified their holdings of the company. Moran Wealth Management LLC lifted its holdings in shares of Halozyme Therapeutics by 0.4% in the 4th quarter. Moran Wealth Management LLC now owns 35,596 shares of the biopharmaceutical company’s stock valued at $2,396,000 after buying an additional 151 shares during the period. Coldstream Capital Management Inc. raised its position in Halozyme Therapeutics by 1.9% in the third quarter. Coldstream Capital Management Inc. now owns 8,914 shares of the biopharmaceutical company’s stock worth $654,000 after acquiring an additional 165 shares in the last quarter. Alps Advisors Inc. raised its position in Halozyme Therapeutics by 3.0% in the third quarter. Alps Advisors Inc. now owns 5,926 shares of the biopharmaceutical company’s stock worth $435,000 after acquiring an additional 170 shares in the last quarter. Pzena Investment Management LLC lifted its holdings in Halozyme Therapeutics by 4.2% in the fourth quarter. Pzena Investment Management LLC now owns 4,278 shares of the biopharmaceutical company’s stock valued at $288,000 after acquiring an additional 171 shares during the period. Finally, EverSource Wealth Advisors LLC boosted its position in shares of Halozyme Therapeutics by 6.9% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,685 shares of the biopharmaceutical company’s stock worth $140,000 after purchasing an additional 174 shares in the last quarter. 97.79% of the stock is owned by hedge funds and other institutional investors.

Halozyme Therapeutics Price Performance

Halozyme Therapeutics stock opened at $71.60 on Friday. Halozyme Therapeutics, Inc. has a 52 week low of $51.06 and a 52 week high of $82.22. The company has a quick ratio of 2.33, a current ratio of 2.76 and a debt-to-equity ratio of 8.81. The firm’s 50-day simple moving average is $66.63 and its 200 day simple moving average is $68.72. The firm has a market capitalization of $8.49 billion, a PE ratio of 25.76, a P/E/G ratio of 0.29 and a beta of 0.88.

Halozyme Therapeutics (NASDAQ:HALO) last posted its earnings results on Monday, May 11th. The biopharmaceutical company reported $1.60 earnings per share for the quarter, beating the consensus estimate of $1.54 by $0.06. The firm had revenue of $376.71 million during the quarter, compared to the consensus estimate of $358.60 million. Halozyme Therapeutics had a net margin of 23.13% and a return on equity of 187.91%. The firm’s revenue for the quarter was up 42.2% on a year-over-year basis. During the same period last year, the firm posted $1.11 EPS. Halozyme Therapeutics has set its FY 2026 guidance at 7.750-8.250 EPS. On average, equities research analysts predict that Halozyme Therapeutics, Inc. will post 7.61 EPS for the current fiscal year.

Insider Transactions at Halozyme Therapeutics

In other news, COO Cortney Caudill sold 20,000 shares of the firm’s stock in a transaction that occurred on Monday, March 9th. The shares were sold at an average price of $67.80, for a total transaction of $1,356,000.00. Following the completion of the transaction, the chief operating officer directly owned 14,366 shares of the company’s stock, valued at $974,014.80. This trade represents a 58.20% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Bernadette Connaughton sold 1,625 shares of Halozyme Therapeutics stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $66.21, for a total value of $107,591.25. Following the transaction, the director owned 43,669 shares of the company’s stock, valued at $2,891,324.49. This represents a 3.59% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 122,107 shares of company stock valued at $8,254,834 in the last ninety days. Corporate insiders own 2.50% of the company’s stock.

Key Headlines Impacting Halozyme Therapeutics

Here are the key news stories impacting Halozyme Therapeutics this week:

• Positive Sentiment: Zacks Research raised earnings forecasts for multiple future periods, including FY2026, FY2027, and FY2028, which strengthens the long-term growth story for Halozyme Therapeutics. Halozyme Therapeutics article
• Positive Sentiment: Analysts also increased estimates for several 2027 quarters, including Q1, Q2, Q3, and Q4, suggesting improving earnings momentum. Halozyme Therapeutics article
• Neutral Sentiment: Some near-term and farther-out estimates were mixed, with a slight cut to Q2 2026 and a reduction in Q1 2028, indicating the outlook improved overall but not across every period. Halozyme Therapeutics article
• Neutral Sentiment: Recent insider sales by the CEO and a director were disclosed, but both were made under pre-arranged 10b5-1 trading plans, which typically makes them less alarming to investors. Halozyme Therapeutics article

Analysts Set New Price Targets

A number of brokerages have recently issued reports on HALO. TD Cowen reiterated a “buy” rating on shares of Halozyme Therapeutics in a report on Wednesday, February 18th. Wall Street Zen raised shares of Halozyme Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, May 16th. Morgan Stanley dropped their target price on shares of Halozyme Therapeutics from $96.00 to $93.00 and set an “overweight” rating for the company in a report on Tuesday, May 12th. UBS Group reiterated a “buy” rating and set a $90.00 price target on shares of Halozyme Therapeutics in a research report on Wednesday. Finally, Benchmark reissued a “buy” rating on shares of Halozyme Therapeutics in a research note on Wednesday. Eight research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $81.60.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.